A Randomized Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes Who Were Previously Treated by Basal Insulin Glargine With Either Metformin or Metformin and Sulfonylurea.

Trial Profile

A Randomized Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes Who Were Previously Treated by Basal Insulin Glargine With Either Metformin or Metformin and Sulfonylurea.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2015

At a glance

  • Drugs Exenatide (Primary) ; Insulin glargine; Insulin lispro; Metformin; Sulfonylureas
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Amylin Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Sep 2013 Secondary endpoint outcomes presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
    • 24 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top